California Monthly Brand Roundup

California Monthly Brand Roundup


California is home to some of the strongest and most well-known brands of cannabis products, and as the referendum on recreational use draws near, all eyes are on the state.  But how do the top manufacturers size up against each other and who is leading in each category? 

Results from Brightfield Group’s new monthly brand tracker show that September was characterized by continued dominance of popular edibles brands Cheeba Chews, Kiva, Korova and Bhang, concentrates brands Moxie Seeds & Extracts and West Coast Cure, and prerolls brand Presidential Rx.  The market for concentrates consolidating, with the number of actively distributed brands down to 428 from 507 in August.  Among makers of topicals, patches, prerolls, and other subcategories, top brands continue to enjoy sizeable leads over competitors, with some dynamic movement among some of the newer and returning brands. 

Edibles

Among edibles manufacturers, Kiva (7.22%, +0.45%) edges out Cheeba Chews (7.15%, -0.02%) for the top spot in September, with market stalwarts Korova (5.41%, +0.1%) and Bhang (3.2%, +0.03%) rounding out the top four. In addition, each of the top four brands continue to dominate their respective subcategories: Cheeba Chews among sugar candies (30.36%, +0.08%), Korova (24.43%, -1.13%) in baked goods, and Kiva (34.11%, +0.75%) and Bhang (12.72%, -0.21%) in chocolates.   Venice Cookie Company (3.00%, +0.25%) maintains its position as the fifth-ranked brand overall, although its market share has expanded by over 0.2%.  In terms of subcategories, however, Venice Cookie Company places in the top ten for a relatively wide variety of products, including chocolates (4.16%), baked goods (1.86%), oils and sprays (0.52%), and drinks (16.38%), where its Cannabis Quencher line leads the market. 

 

 

california edibles september

Concentrates

In the concentrates category, Moxie Seeds & Extracts (2.58%, +0.69%) widens its lead over the competition, expanding its lead over second-place West Coast Cure (0.99%, +0.35%) to over 1.5% percent.  Overall, the market continues a gradual trend towards consolidation, with 4 out of the top ten brands now showing market shares over 1%, compared to only one brand with a market share over 1% one month earlier.  Gold Coast Extracts (1.01%, +0.21%) exhibits strong growth, climbing from sixth to third place, while brands such as Delta 9 (0.77%, -0.13%) and Tetra Labs (0.65%, -0.13%) maintain positions in the top ten. Bhang, who once was among the top five concentrates manufacturers prior to the Med-West raid, has fallen out of the top ten again, reaching only 13th place in concentrates for September.    Terra Tech’s IVXX brand jumped into 3rd place in waxes, though their shatters and cartridges still fail to make the top ten statewide though have stronger distribution in the Bay Area.  The California concentrates market continues to be a crowded and competitive venue, with 428 actively distributed brands identified in September 2016.

 

california september concentrates shares

Others

Our analysis of other subcategories shows the continued pattern of one or two dominant brands per field.  Pure Ratios (12.85%, +3.56%) continues to be ranked as the state’s largest maker of transdermal patches, Tetra Labs (16.93%, - 0.34%) continues to lead capsule manufacturers, Emu 420 (16.00%, - 1.38%) maintains its dominance of the topicals category, and Presidential Rx (29.68%, +8.47%) continues to be the state’s top-ranked maker of pre-rolls.   Caviar Gold (1.40%, -.77%) stumbles, falling out of the top ten in Others entirely, and falling from 6.32% of pre-roll in August to only 2.15% in September.  Market share for Care By Design (.97%, +.51%), a CBD rich producer of tinctures, pills, cartridges and oils, has more than doubled, bouncing back from the company’s June raid.  Common to leading brands is a wide distribution among state dispensaries and a variety of available products.

 

California Others Shares September

Data is based on our multi-source methodology, which includes surveys with thousands of California medical marijuana patients, menu audits of hundreds of dispensaries across the state, and in depth interviews with dispensary owners, among other sources.  For more information on our methodology, for additional brand, market and consumer insights in the cannabis industry, or for custom research needs, visit us at brightfieldgroup.com or reach out at contact@brightfieldgroup.com.  






Also in News

HelloMD and Brightfield Group to Explore Effectiveness of CBD-only Cannabis Product as an Alternative to Prescribed Medication
HelloMD and Brightfield Group to Explore Effectiveness of CBD-only Cannabis Product as an Alternative to Prescribed Medication

SAN FRANCISCO, CA – May 16, 2017HelloMD, one of the nation’s largest community of medical cannabis patients, experts and trusted brands, announced today the launch a substantial survey concerning cannabis, and specifically, CBD usage. Performed in collaboration with Brightfield Group, the premier market research firm focused on the legal cannabis industry, HelloMD will seek insights from over 150,000 of its registered participants regarding CBD usage, patient knowledge, perceptions and misconceptions concerning CBD.

View full article →

Big Players in the Washington Cannabis Market
Big Players in the Washington Cannabis Market

Flourishing cannabis product sales in Washington have been attracting several companies to this market. Phat Panda and Northwest Cannabis Solutions are two companies that are establishing a strong presence in this market, where medical use has been legal since 1998, and recreational purchases were made available in 2014.

View full article →

Brightfield Group investigates the economic impact of cannabis legalization

Brightfield Group is helping business leaders respond to cannabis legalization by offering new market research products tailored to this evolving industry. According to the research firm, California's recent legalization of recreational cannabis could have a profound economic impac

View full article →